Growth & GH-Axis

IGF-1 DES

IGF-1 analog (truncated des(1-3) IGF-1 variant)

A truncated analog of insulin-like growth factor-1 studied in localized growth-factor research.

Also referenced as: DES(1-3)IGF-1, IGF-1 des(1-3)

67 aat½ Very short in circulation (minutes), reflecting IGF-1's rapid clearance when not bound to IGFBPs

Overview

IGF-1 DES (DES(1-3)IGF-1) is a naturally occurring and synthetically produced truncated variant of insulin-like growth factor 1, lacking the first three N-terminal amino acids (Gly-Pro-Glu) of the 70-residue mature IGF-1.

At a glance

ClassIGF-1 analog (truncated des(1-3) IGF-1 variant)

CategoryGrowth & GH-Axis

Chain length67 amino acids

Molecular weightApproximately 7372 g/mol

Half-lifeVery short in circulation (minutes), reflecting IGF-1's rapid clearance when not bound to IGFBPs

Typical formLyophilized powder

AliasesDES(1-3)IGF-1, IGF-1 des(1-3)

Use designationResearch / in-vitro only

Regulatory statusIGF-1 DES is not approved by the FDA or EMA for any indication; it is used in research contexts only and is not an approved medicine.

What IGF-1 DES does

IGF-1 DES (DES(1-3)IGF-1) is a naturally occurring, truncated variant of insulin-like growth factor 1 that is missing the first three N-terminal amino acids. Unlike the GHRH analogs and ghrelin mimetics in this catalog — which work indirectly by triggering the pituitary to release GH — IGF-1 DES is a direct-acting effector that binds and activates the IGF-1 receptor itself, driving anabolic signaling (PI3K/Akt and MAPK pathways) in muscle and other tissues without any need for the pituitary. This is the fundamental mechanistic difference: it is downstream of GH, delivering the anabolic signal directly.

The deletion of those three N-terminal residues has a specific and well-documented consequence: it drastically reduces the peptide's affinity for IGF binding proteins (roughly a 25-fold drop in IGFBP-3 binding). Normally IGFBPs sequester circulating IGF-1 and limit how much is free to act; by escaping this buffering, DES(1-3)IGF-1 remains free and is substantially more potent at activating the receptor in the tissue where it is present — in cell and animal studies it can be several-fold more mitogenic than intact IGF-1. Its half-life is short (minutes), so its action tends to be intense and localized rather than systemic.

Evidence is preclinical (in-vitro cell and rodent studies); DES(1-3)IGF-1 is a research reagent, not an approved therapeutic, and human efficacy for muscle growth is not established.

Effects reported in research

Directly activated the IGF-1 receptor to drive anabolic PI3K/Akt signaling in muscle cells, bypassing the GH/pituitary axis (in-vitro).
Bound IGF binding proteins with ~25-fold reduced affinity (IGFBP-3), escaping the sequestration that limits ordinary IGF-1.
Showed several-fold greater mitogenic potency than intact IGF-1 in cell-culture assays because it stays free/unbound.
Stimulated proliferation and protein synthesis in muscle and other cell types (preclinical).
Acted with short half-life producing intense, localized rather than sustained systemic effects.
Promoted cell growth in a variety of tissue models responsive to IGF-1 signaling (in-vitro/animal).
Human efficacy for muscle growth/recovery is unproven; evidence is preclinical and research-use only.

Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.

Mechanism of action

IGF-1 DES is an agonist of the IGF-1 receptor, activating the same anabolic and proliferative signaling as native IGF-1. The removal of the N-terminal tripeptide markedly reduces its binding to IGF-binding proteins (IGFBPs), so a larger fraction remains free and it is reported to be more potent locally than full-length IGF-1. Its reduced IGFBP binding also contributes to a shorter systemic half-life.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which IGF-1 DES appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Key characteristics

Truncated form lacking the N-terminal Gly-Pro-Glu (des 1-3) of IGF-1
Reduced affinity for IGFBPs means more free, active peptide locally
Reported to be more potent than native IGF-1 in some in-vitro/preclinical models
Very short systemic half-life relative to IGFBP-bound native IGF-1
Acts through the IGF-1 receptor, downstream of GH in the somatotropic axis

Reported research dosing reference only

Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. IGF-1 DES is a research compound.

IGF-1 DES is referenced in the research literature in the low-microgram-per-administration range, reflecting its high potency and short duration. These are reference figures for research context only, not dosing guidance for humans.

Common research-protocol reference: ~50-150 mcg per administration

Reported frequencyReported around administration timing due to the very short (~20-30 min) half-life

ReconstitutionLyophilized; typically reconstituted with bacteriostatic water or dilute acetic acid for research use

~10x per-unit potency of native IGF-1 owing to reduced IGFBP binding; very short half-life. Reference figures only, not human dosing guidance.

How it compares

IGF-1 DES differs from native and LR3 IGF-1 by its N-terminal truncation (des 1-3), which lowers IGFBP binding and increases local potency but with a short systemic half-life, unlike the long-acting LR3 variant.

Commonly studied alongside

Compounds frequently researched together with IGF-1 DES in the literature. Cross-referenced for research context — not a usage or combination recommendation.

IGF-1 LR3The two IGF-1 analogs are frequently compared/co-studied for short-acting vs long-acting IGF-1R activation.CJC-1295 (with DAC)GHRH-driven GH/IGF-1 elevation is studied alongside a direct IGF-1 receptor agonist.

Compare and calculate

Side-by-side pages for the pairings the literature already documents for IGF-1 DES, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

Avoid repeated freeze-thaw cycles
Verify supplier lot and Certificate of Analysis
Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

IGF-1 DES sits in the Growth & GH-Axis area of the PeptiDex library.

Research Supplier Listing

Where researchers source IGF-1 DES

For researchers studying IGF-1 DES, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.

Explore Research Suppliers →

PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.

Frequently asked questions

What is IGF-1 DES?

IGF-1 DES, or DES(1-3) IGF-1, is a truncated analog of insulin-like growth factor-1 that lacks the first three N-terminal amino acids (Gly-Pro-Glu), leaving a 67-amino-acid peptide. It is an IGF-1 receptor agonist studied for its markedly higher per-unit potency than native IGF-1.

How does IGF-1 DES differ from IGF-1 LR3?

Both are IGF-1 analogs with reduced binding to IGF-binding proteins, but they differ sharply in duration: IGF-1 DES has a very short half-life (~20-30 minutes) and is studied for localized, short-acting effects, while IGF-1 LR3 has an extended half-life (~20-30 hours) supporting systemic, less-frequent dosing.

Why is IGF-1 DES more potent than native IGF-1?

Removing the first three N-terminal residues sharply reduces the peptide's affinity for IGF-binding proteins (IGFBPs), leaving more free peptide available to activate the IGF-1 receptor. The research literature reports this yields roughly a 10-fold increase in in-vivo potency per unit dose.

What does IGF-1 DES's short half-life imply for research?

With a half-life of only ~20-30 minutes, IGF-1 DES is described in the research literature as suited to localized, site-directed study designs rather than sustained systemic exposure, because its activity fades quickly after administration.

Is IGF-1 DES an approved drug?

No. IGF-1 DES is not an approved medication and is used only as a research chemical for in-vitro and preclinical study.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

References

Primary literature indexed in PubMed for IGF-1 DES. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).

Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I Int J Biochem Cell Biol, 1996. PubMed 8930132
Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice J Endocrinol, 1990. PubMed 2280209

Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.